AmericaFirst Defensive Growth & Income Portfolio Series 2’s GSK GSK Stock Holding History

AmericaFirst Defensive Growth & Income Portfolio Series 2’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$299K	Buy	+5,547	New	+$296K	0.38%	92

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AmericaFirst Defensive Growth & Income Portfolio Series 2's GSK Position: Q2 2017 in Review

AmericaFirst Defensive Growth & Income Portfolio Series 2 opened a new position in GSK (GSK) in Q2 2017: 5,547 shares worth $299K. The stake represents 0.38% of the portfolio and ranks #92 among its holdings.

780 funds tracked by Wall St. Rank hold GSK as of Q2 2017.

AmericaFirst Defensive Growth & Income Portfolio Series 2 held 5,547 shares of GSK worth $299K as of Q2 2017.
GSK was a new AmericaFirst Defensive Growth & Income Portfolio Series 2 position in Q2 2017.
GSK made up 0.38% of AmericaFirst Defensive Growth & Income Portfolio Series 2's portfolio in Q2 2017, its #92 holding.
780 funds tracked by Wall St. Rank held GSK as of Q2 2017.

Based on AmericaFirst Defensive Growth & Income Portfolio Series 2's 13F filing for Q2 2017, filed 15 Aug 2017.